Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.

doi:10.18632/aging.204038

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.

Aging - 27 Apr 2022

McCubrey James A, Meher Akshaya K, Akula Shaw M, Abrams Stephen L, Steelman Linda S, LaHair Michelle M, Franklin Richard A, Martelli Alberto M, Ratti Stefano, Cocco Lucio, Barbaro Fulvio, Duda Przemysław, Gizak Agnieszka

Abstract excerpt

TP53 is a master regulator of many signaling and apoptotic pathways involved in: aging, cell cycle progression, gene regulation, growth, apoptosis, cellular senescence, DNA repair, drug resistance, malignant transformation, metastasis, and metabolism. Most pancreatic cancers are classified as pancreatic ductal adenocarcinomas (PDAC). The tumor suppressor gene TP53 is mutated frequently (50-75%) in PDAC. Different...

Topics

Carcinoma, Pancreatic Ductal
Cell Line, Tumor
Cell Proliferation
Dietary Supplements
ErbB Receptors
Gain of Function Mutation
Glycogen Synthase Kinase 3
Humans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mechanistic Target of Rapamycin Complex 1

Mitogen-Activated Protein Kinase Kinases

Mutation

Pancreatic Neoplasms

Phosphatidylinositol 3-Kinases

Phosphoinositide-3 Kinase Inhibitors

Proto-Oncogene Proteins p21(ras)

Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 35477123
DOI: 10.18632/aging.204038
PMCID: PMC9085237

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.PMID 35477123Read ↗

Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53.Semantic proximity Read ↗

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.Semantic proximity Read ↗

Advances in understanding the roles of TP53 mutations in pancreatic and hepatobiliary cancers.Semantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.Semantic proximity Read ↗

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersSemantic proximity Read ↗

TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Drug-Induced p53 Activation Limits Pancreatic Cancer InitiationSemantic proximity Read ↗

Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.Semantic proximity Read ↗

Lipidome atlas of p53 mutant variants in pancreatic cancer.Semantic proximity Read ↗

TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.